Skip to main content

Table 4 Summary statistics for the TNAS v3.0 items collected at the initial assessment, by cohort

From: The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment

 

All N = 60

 

Bortezomib n = 20

Oxaliplatin

n = 20

Taxane–Platinum

n = 20

Mean (SD)

Prevalencea

Percentage of Missing Itemsb

Mean (SD)

Mean (SD)

Mean (SD)

Numbness in arms, legs, hands, or feet

4.88 (2.8)

92%

0

3.65 (2.4)

5.00 (2.9)

6.00 (2.7)

Tingling in arms, legs, hands, or feet

4.69 (3.0)

92%

0.18%

3.70 (2.6)

4.60 (3.2)

5.84 (2.9)

Pain in arms, legs, hands, or feet

3.92 (3.5)

75%

0

3.25 (3.2)

2.95 (3.1)

5.55 (3.7)

Trouble walking

3.62 (3.2)

73%

0

2.60 (2.6)

3.05 (2.9)

5.20 (3.6)

Disturbed sleep

3.58 (3.3)

77%

0

3.55 (3.0)

2.70 (3.4)

4.50 (3.5)

Trouble with balance or falling

3.05 (3.1)

75%

0.18%

2.63 (2.5)

2.45 (2.9)

4.05 (3.6)

Feelings of coldness in hands or feet

2.95 (3.1)

67%

0

2.55 (2.8)

3.05 (3.1)

3.25 (3.4)

Hot or burning sensations in arms, legs, hands, or feet

2.59 (3.1)

58%

0.18%

2.11 (2.5)

1.75 (2.7)

3.90 (3.5)

Difficulty using hands or fingers

2.53 (2.9)

65%

0

2.10 (2.4)

2.35 (3.0)

3.15 (3.4)

  1. Abbreviation: TNAS Treatment-induced Neuropathy Assessment Scale
  2. a Percentage of patients rating ≥ 1 on a 0–10 scale
  3. b On the 9-item TNAS, the denominator was 540 (9 item times 60 patients). Missing item responses were from 3 patients